The phrase
"oncogenic drivers" refers to specific genes or genetic mutations that can cause the development and progression of cancer. These drivers push cells to grow and divide uncontrollably, leading to the formation of tumors. Identifying
oncogenic drivers helps researchers better understand the underlying mechanisms of cancer and develop targeted therapies to treat it.
Full definition
Patients with adenocarcinoma have a high probability of having mutated
oncogenic driver genes in their tumors.
Project Title: Functional in vivo screening of
novel oncogenic driver mutations in a zebra fish melanoma model
Having realized my passion for the same and determined about improvising medical treatment for melanoma cancer I am now working on «Functional in vivo screening of novel
oncogenic driver mutations in a zebrafish melanoma model» under the guidance of Prof. Levesque Mitchell Paul.
Furthermore; novel targeted therapies with MAPK pathway kinase inhibitors (KIs) have been developed thanks to the discovery that BRAF and NRAS mutations which are among the
major oncogenic drivers of melanoma proliferation and survival [12].
The study, published in the May 21 issue of The Journal of the American Medical Association, investigated 10 highly mutated and altered genes that contribute to cancer progression,
termed oncogenic driver genes, in more than 1,000 lung cancer patients.
As
new oncogenic driver genes are identified, the testing process becomes less efficient because more genes need to be analyzed in limited amounts of tumor tissue.
It is initiated by chromosomal translocation t (11; 22)(q24; q12), which creates the fusion protein and
oncogenic driver EWS / FLI.
DENVER — The use of hybrid capture - based (HC - based) next - generation sequencing (NGS) to identify
targetable oncogenic drivers in patients with lung adenocarcinoma results in the detection of genomic alterations (GAs) not identified in routine screening, and impacts treatment decisions and clinical outcomes.
Together, these studies indicate that MELK can be a
potent oncogenic driver, when it is aberrantly overexpressed and that this oncogenic potential relies on its kinase activity.
We have hundreds of these gene pairs in hand and are now developing drugs targeting the synthetic lethal partner of
major oncogenic drivers.
The afternoon session began with from Zurich student Ishani Banik (SWISS2) who presented her ongoing work using zebrafish melanoma models to perform in vivo screening of functional
novel oncogenic driver mutations.
The researchers found that those patients who had targeted treatment against
an oncogenic driver gene survived longer than those patients who did not.